New drug approvals in acute myeloid leukemia: what’s the best end point?
Crossref DOI link: https://doi.org/10.1038/leu.2015.262
Published Online: 2015-12-18
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Estey, E
Othus, M
Lee, S J
Appelbaum, F R
Gale, R P
Text and Data Mining valid from 2015-12-18
Version of Record valid from 2015-12-18
Article History
First Online: 18 December 2015
Competing interests
: RPG is associated with Celgene Corp. His opinions are his own and not necessarily those of Celgene Corp.